Neurology, Immunology.Company develops monoclonal antibody (mAb) therapies for the treatment of substance abuse, among other conditions. mAb medications can bind to toxic and addictive compounds in the bloodstream and restrict their transport into the brain, thereby counteracting their ‘rewarding effects’ and reducing damage. The primary indications for the company’s antibody-based therapies is treatment of PCP, methamphetamine, amphetamine and ecstasy abuse, with the first clinical trial focused on testing the efficacy of PCP-mAb treatment of acute PCP overdose. According to a recent study, government spending related to smoking, alcohol and drug abuse is estimated at nearly $500 billion. The company has received $3 million in funding from the NIH’s National Institute on Drug Abuse over the last five years, and has a face-to-face pre-IND meeting with FDA scheduled in September 2009. Founded: 2004, Employees 2.